McKesson Corporation

The filings describe a company that is growing through acquisitions while reorganizing its structure. McKesson now reports four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company announced its intention to separate Medical-Surgical Solutions into an independent company, and on April 20, 2026 it agreed that funds affiliated with Apollo Global Management would invest approximately $1.25 billion for about a 13% minority stake in that segment’s convertible preferred equity. The transaction is subject to regulatory approvals and customary closing conditions. On the financing side, May 30, 2025 notes totaling $2.0 billion (4.65% notes due 2030, 4.95% notes due 2032, and 5.25% notes due 2035) funded the Core Ventures purchase. The $1.0 billion 364-Day Credit Facility was terminated on April 24, 2026 and replaced with a 2026 5-Year Facility, and the MD&A excerpt does not give that facility’s terms. Restructuring charges were $170 million in fiscal 2026. No forensic scores are on file for this review, so this synthesis does not assess Beneish M-Score, Piotroski F-Score, Altman Z-Score, or Fog Index results. Plainly, the Beneish M-Score is a screen for patterns that sometimes accompany earnings manipulation, the Piotroski F-Score counts basic financial-health signals, the Altman Z-Score is a bankruptcy-risk screen, and the Fog Index estimates how hard a document is to read. Readers may want to look at Financial Note 17, Commitments and Contingent Liabilities, for the opioid litigation details, and at Financial Note 11, Debt and Financing Activities, for the terms of the notes and credit facilities before drawing conclusions about the company’s financial position.

Catalyst.Revenue for fiscal 2026 (year ended March 31, 2026) rose about 12% to $403.43 billion from $359.05 billion, and gross profit rose 9%, according to the MD&A. The executive summary points to acquisitions that feed the new Oncology & Multispecialty segment: PRISM Vision, acquired April 1, 2025 for $875 million for an 80% interest, and Core Ventures, acquired June 2, 2025 for $2.5 billion for a 70% controlling interest. Diluted earnings per share rose to $38.38 from $25.72. That increase also reflects a $480 million net gain from the Norway sale, which the filing records within total operating expenses.

Hidden risk.The most material tension a casual reader could miss is opioid exposure. The risk factors state that McKesson is a defendant in many controlled-substance lawsuits brought by governmental entities and businesses, some raising novel liability theories. The company is also subject to state-court consent decrees governing its distribution of controlled substances. The filing says outcomes can include monetary damages, penalties, and required operational changes, and that cases can take years to resolve. Separately, the Norway gain is a one-time item inside operating expenses, so it affects year-over-year comparisons of profit and operating expenses.